These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26209955)

  • 21. Preclinical evaluation of biomarkers for response monitoring to the MET inhibitor BAY-853474.
    Klotz M; Schmid E; Steiner-Hahn K; Rose T; Laube J; Roese L; Henderson D; Krahn T; von Ahsen O
    Biomarkers; 2012 Jun; 17(4):325-35. PubMed ID: 22452362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting In Vivo Efficacy from In Vitro Data: Quantitative Systems Pharmacology Modeling for an Epigenetic Modifier Drug in Cancer.
    Bouhaddou M; Yu LJ; Lunardi S; Stamatelos SK; Mack F; Gallo JM; Birtwistle MR; Walz AC
    Clin Transl Sci; 2020 Mar; 13(2):419-429. PubMed ID: 31729169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A mathematical model to study the effects of drugs administration on tumor growth dynamics.
    Magni P; Simeoni M; Poggesi I; Rocchetti M; De Nicolao G
    Math Biosci; 2006 Apr; 200(2):127-51. PubMed ID: 16516246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
    Rocchetti M; Germani M; Del Bene F; Poggesi I; Magni P; Pesenti E; De Nicolao G
    Cancer Chemother Pharmacol; 2013 May; 71(5):1147-57. PubMed ID: 23430120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice.
    Ji XW; Ji SM; Li RT; Wu KH; Zhu X; Lu W; Zhou TY
    Acta Pharmacol Sin; 2016 Jun; 37(6):825-33. PubMed ID: 27133303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Array of translational systems pharmacodynamic models of anti-cancer drugs.
    Ait-Oudhia S; Mager DE
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):549-565. PubMed ID: 27771815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment and characterization of cell lines from chromosomal instable colorectal cancer.
    Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M
    World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
    Wong H; Belvin M; Herter S; Hoeflich KP; Murray LJ; Wong L; Choo EF
    J Pharmacol Exp Ther; 2009 Apr; 329(1):360-7. PubMed ID: 19147858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts.
    Gong IY; Teft WA; Ly J; Chen YH; Alicke B; Kim RB; Choo EF
    Breast Cancer Res Treat; 2013 May; 139(1):61-9. PubMed ID: 23605084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor.
    Titze MI; Schaaf O; Hofmann MH; Sanderson MP; Zahn SK; Quant J; Lehr T
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):545-558. PubMed ID: 28243682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing cytotoxic treatment effects in preclinical tumor xenograft models.
    Wu J; Houghton PJ
    J Biopharm Stat; 2009 Sep; 19(5):755-62. PubMed ID: 20183441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A minimal model of tumor growth inhibition.
    Magni P; Germani M; De Nicolao G; Bianchini G; Simeoni M; Poggesi I; Rocchetti M
    IEEE Trans Biomed Eng; 2008 Dec; 55(12):2683-90. PubMed ID: 19126447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.
    Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
    J Pharmacol Exp Ther; 2014 Oct; 351(1):67-76. PubMed ID: 25073473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Translational pharmacokinetic/pharmacodynamic analysis in cancer pharmacology: a tool to maximize the value of antitumor efficacy from tumor bearing mice.
    Wong H; Gould SE
    Drug Discov Today Technol; 2016; 21-22():51-56. PubMed ID: 27978988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
    Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
    PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib.
    Tosca EM; Terranova N; Stuyckens K; Dosne AG; Perera T; Vialard J; King P; Verhulst T; Perez-Ruixo JJ; Magni P; Poggesi I
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):117-128. PubMed ID: 34786600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonlinear model predictive control for dosing daily anticancer agents using a novel saturating-rate cell-cycle model.
    Florian JA; Eiseman JL; Parker RS
    Comput Biol Med; 2008 Mar; 38(3):339-47. PubMed ID: 18222419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.